Thousands Of Jobs May Go At Novartis But Worker Headcount To Stay Flat
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis plans to support new product launches and other activities around the world by re-allocating up to 4,000 positions, in order to make productivity gains.
You may also be interested in...
Ranbaxy Talks Up De-risking Strategy To Offset Impact Of Toansa Site Ban
Ranbaxy fielded a volley of questions during a fourth quarter earnings call on the impact of the latest ban imposed by FDA on its Toansa, India site. Contrary to general estimates, Ranbaxy clarified the impact of the ban will be very limited on its North American business.
Ranbaxy Talks Up De-risking Strategy To Offset Impact Of Toansa Site Ban
Ranbaxy fielded a volley of questions during a fourth quarter earnings call on the impact of the latest ban imposed by FDA on its Toansa, India site. Contrary to general estimates, Ranbaxy clarified the impact of the ban will be very limited on its North American business.
European Notebook: Price Freezes, European Elections To Feature In 2014
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.